FDA approves atezolizumab with chemotherapy for stage III colon cancer
The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy as adjuvant treatment for adult and pediatric patients aged 2 years or older with stage III mismatch repair-deficient colon cancer.
